Catalent Issues Initial Public Offering - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Catalent Issues Initial Public Offering

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 8

Catalent Inc. has completed an initial public offering, garnering more than $870 million, and is now a publicly traded company on the New York Stock Exchange (NYSE).

On July 31, the company announced the pricing of its initial public offering of 42,500,000 shares of its common stock at $20.50 per share. The shares began trading on the NYSE on July 31, 2014 under the ticker symbol CTLT, and the offering is expected to close on August 5, 2014, subject to customary closing conditions, according to company reports. Catalent has granted the underwriters a 30-day option to purchase up to an additional 6,375,000 at the initial public offering price.

The proceeds of the offering will be used to redeem more than $800 million (estimated) of Catalent’s currently outstanding debt, the company reports.  “This will allow the company to significantly reduce its interest expense, enable future potential internal and external growth strategies, and to continue our growth-biased investments into new technologies, capabilities, global development and manufacturing facilities and capacity,” a company statement reports.

Recent investments include new facilities for its softgel and clinical supply businesses in China and Brazil; a  $20 million Biologics Center of Excellence for cell line development and biomanufacturing in Madison, WI; and a $35 million ongoing expansion or the company’s Oral Advanced Technologies manufacturing site in Winchester, KY.

Source: Catalent Inc.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here